We showed recently that increasing kidney epoxyeicosatrienoic acids (EETs) by blocking soluble epoxide hydrolase (sEH), an enzyme responsible for EETs degradation, retarded the development of renal dysfunction and progression of aorto-caval fistula(ACF)-induced congestive heart failure (CHF) in Ren-2 transgenic hypertensive rats (TGR). In that study the final survival rate of untreated ACF TGR was only 14 % but increased to 41 % after sEH blockade. Here we examined if sEH inhibition added to renin-angiotensin system (RAS) blockade would further enhance protection against ACF-induced CHF in TGR. The treatment regimens were started one week after ACF creation and the follow-up period was 50 weeks. RAS was blocked using angiotensin-converting enzyme inhibitor (ACEi, trandolapril, 6 mg/l) and sEH with an sEH inhibitor (sEHi, c-AUCB, 3 mg/l). Renal hemodynamics and excretory function were determined two weeks post-ACF, just before the onset of decompensated phase of CHF. 29 weeks post-ACF no untreated animal survived. ACEi treatment greatly improved the survival rate, to 84 % at the end of study. Surprisingly, combined treatment with ACEi and sEHi worsened the rate (53 %). Untreated ACF TGR exhibited marked impairment of renal function and the treatment with ACEi alone or combined with sEH inhibition did not prevent it. In conclusion, addition of sEHi to ACEi treatment does not provide better protection against CHF progression and does not increase the survival rate in ACF TGR: indeed, the rate decreases significantly. Thus, combined treatment with sEHi and ACEi is not a promising approach to further attenuate renal dysfunction and retard progression of CHF.

Center for Experimental Medicine Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Cardiology Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Entomology and UCD Cancer Center University of California Davis CA USA

Department of Internal Medicine 1 Cardiology University Hospital Olomouc and Palacký University Olomouc Czech Republic

Department of Pathophysiology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Pharmacology and Toxicology Medical College of Wisconsin Milwaukee WI USA

Department of Pharmacology Kagawa University Kagawa Japan

Department of Renal and Body Fluid Physiology Mossakowski Medical Research Centre Polish Academy of Science Warsaw Poland

000      

00000naa a2200000 a 4500

001      

bmc18040228

003      

CZ-PrNML

005      

20220531090732.0

007      

ta

008      

181214s2018 xr d f 000 0|eng||

009      

AR

024    7_

$a 10.33549/physiolres.933757 $2 doi

035    __

$a (PubMed)29527914

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xr

100    1_

$a Kala, Petr $7 xx0273373

245    10

$a Effect of angiotensin-converting enzyme blockade, alone or combined with blockade of soluble epoxide hydrolase, on the course of congestive heart failure and occurrence of renal dysfunction in Ren-2 transgenic hypertensive rats with aorto-caval fistula / $c P. Kala, L. Sedláková, P. Škaroupková, L. Kopkan, Z. Vaňourková, M. Táborský, A. Nishiyama, S. H. Hwang, B. D. Hammock, J. Sadowski, V. Melenovský, J. D. Imig, L. Červenka

520    9_

$a We showed recently that increasing kidney epoxyeicosatrienoic acids (EETs) by blocking soluble epoxide hydrolase (sEH), an enzyme responsible for EETs degradation, retarded the development of renal dysfunction and progression of aorto-caval fistula(ACF)-induced congestive heart failure (CHF) in Ren-2 transgenic hypertensive rats (TGR). In that study the final survival rate of untreated ACF TGR was only 14 % but increased to 41 % after sEH blockade. Here we examined if sEH inhibition added to renin-angiotensin system (RAS) blockade would further enhance protection against ACF-induced CHF in TGR. The treatment regimens were started one week after ACF creation and the follow-up period was 50 weeks. RAS was blocked using angiotensin-converting enzyme inhibitor (ACEi, trandolapril, 6 mg/l) and sEH with an sEH inhibitor (sEHi, c-AUCB, 3 mg/l). Renal hemodynamics and excretory function were determined two weeks post-ACF, just before the onset of decompensated phase of CHF. 29 weeks post-ACF no untreated animal survived. ACEi treatment greatly improved the survival rate, to 84 % at the end of study. Surprisingly, combined treatment with ACEi and sEHi worsened the rate (53 %). Untreated ACF TGR exhibited marked impairment of renal function and the treatment with ACEi alone or combined with sEH inhibition did not prevent it. In conclusion, addition of sEHi to ACEi treatment does not provide better protection against CHF progression and does not increase the survival rate in ACF TGR: indeed, the rate decreases significantly. Thus, combined treatment with sEHi and ACEi is not a promising approach to further attenuate renal dysfunction and retard progression of CHF.

650    _2

$a inhibitory ACE $x terapeutické užití $7 D000806

650    _2

$a zvířata $7 D000818

650    _2

$a arteriovenózní píštěl $7 D001164

650    _2

$a benzoáty $x farmakologie $x terapeutické užití $7 D001565

650    _2

$a preklinické hodnocení léčiv $7 D004353

650    _2

$a kombinovaná farmakoterapie $7 D004359

650    _2

$a epoxid hydrolasy $x antagonisté a inhibitory $7 D004851

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a srdeční selhání $x komplikace $x farmakoterapie $x mortalita $7 D006333

650    _2

$a indoly $x terapeutické užití $7 D007211

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a krysa rodu Rattus $7 D051381

650    _2

$a potkani Sprague-Dawley $7 D017207

650    _2

$a potkani transgenní $7 D055647

650    _2

$a renální insuficience $x etiologie $x prevence a kontrola $7 D051437

650    _2

$a močovina $x analogy a deriváty $x farmakologie $x terapeutické užití $7 D014508

655    _2

$a časopisecké články $7 D016428

700    1_

$a Sedláková, Lenka, $d 1992- $7 xx0273377 $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

700    1_

$a Škaroupková, Petra $7 xx0117683 $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

700    1_

$a Kopkan, Libor $7 xx0107287 $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

700    1_

$a Vaňourková, Zdeňka, $d 1973- $7 xx0074217 $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

700    1_

$a Táborský, Miloš, $d 1962- $7 jn20010310074 $u Department of Internal Medicine I, Cardiology, University Hospital Olomouc and Palacký University, Olomouc Czech Republic

700    1_

$a Nishiyama, A. $u Department of Pharmacology, Kagawa University, Kagawa, Japan

700    1_

$a Hwang, S. H. $u Department of Entomology and UCD Cancer Center, University of California, Davis, CA, USA

700    1_

$a Hammock, B. D. $u Department of Entomology and UCD Cancer Center, University of California, Davis, CA, USA

700    1_

$a Sadowski, J. $u Department of Renal and Body Fluid Physiology, Mossakowski Medical Research Centre, Polish Academy of Science, Warsaw, Poland

700    1_

$a Melenovský, Vojtěch $7 xx0160847 $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

700    1_

$a Imig, J. D. $u Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA

700    1_

$a Červenka, Luděk, $d 1967- $7 xx0037105 $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Department of Pathophysiology, Second Faculty of Medicine, Charles University, Prague, Czech Republic

773    0_

$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 67, č. 3 (2018), s. 401-415

856    41

$u https://pubmed.ncbi.nlm.nih.gov/29527914 $y Pubmed

910    __

$a ABA008 $b A 4120 $c 266 $y 4 $z 0

990    __

$a 20181214 $b ABA008

991    __

$a 20220531090729 $b ABA008

999    __

$a ok $b bmc $g 1369651 $s 1037291

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2018 $b 67 $c 3 $d 401-415 $e 20180312 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824

LZP    __

$b NLK118 $a Pubmed-20181214